Allergic Conjunctivitis Market

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,850	140 Pages	Fortune Business Insights Pvt. Ltd.	October, 2024	FOB19224327

Best Price Guarantee
Price	from $4,850
Length	140 Pages
Publisher	Fortune Business Insights Pvt. Ltd.
Published Date	October, 2024
SKU	FOB19224327

Allergic Conjunctivitis Market

Growth Factors of Allergic Conjunctivitis Market

The allergic conjunctivitis market size was valued at USD 3.04 billion in 2023, and the market is now projected to grow from USD 3.20 billion in 2024 to USD 4.96 billion by 2032, exhibiting a CAGR of 5.6% during the forecast period of 2024-2032.

Pandemic negatively impacted allergic conjunctivitis market growth. However, in 2021, the market experienced pre-pandemic increase due to behind schedule remedies and new product launches. In 2022 and 2023, the marketplace additionally experienced pre-pandemic growth rate, and is projected to develop at an extensive CAGR from 2024.

Ocular allergic reactions are a widespread marketplace motive force, affecting over 15% of the global population. These allergies affect multiple frame organs, main to symptoms associated with a couple of systems. The ocular element is the most prominent and disabling function, causing chronic signs like itching and watering of the eyes. The demand for therapeutics like antihistamines and mast mobile stabilizers has expanded appreciably due to the growing affected person population. Research display that the prevalence of this circumstance has significantly elevated over the last 40 years.

The market fashion is transferring from prescription-best therapeutics to Over-The-Counter (OTC) pills, presenting convenience and affordability. This shift has brought about multiplied adoption of these therapeutics. In July 2020, the U.S. FDA approved Alcon's Pataday Once Daily Relief (olopatadine hydrochloride, 0.7%) to transition from prescription-simplest to OTC. This method, monitored with the aid of the FDA, is taken into consideration scientifically rigorous and quite regulated, presenting access to a growing variety of therapeutics for ocular hypersensitive reactions sufferers. These tendencies are predicted to open up a brand-new affected person population for organizations in the marketplace and contribute considerably to the marketplace's surge within the forecast duration.

Comprehensive Analysis of Allergic Conjunctivitis Market

The global marketplace is segmented into antihistamines and mast cell stabilizers, corticosteroids, and others. The antihistamines and mast mobile stabilizers section are expected to broaden at a huge CAGR due to their reputation due to the fact the gold popular remedy. The corticosteroids phase is anticipated to have the second-maximum marketplace percentage in 2023 because of their utilization in excessive ocular allergy cases. The market is divided into moderate and excessive disease sorts, with excessive allergic conjunctivitis keeping the very best marketplace percentage because of immoderate medical expenditure. The marketplace is also break up into health centre pharmacies, drug stores and retail pharmacies, and on-line pharmacies. Hospital pharmacies dominate the market due to thorough examinations via educated medical professionals. Drug stores and retail pharmacies account for the second-highest market in 2020 because of rising call for over-the-counter medicines. Online pharmacies are expected to witness the highest increase rate because of their comfort and ease of procurement.

The North America region lead the allergic conjunctivitis market share by benefitting a market size of USD 1.48 billion in 2023 due to its widespread awareness of ocular allergies, strong prevalence of the disease, and the presence of major players launching advanced drugs.

The marketplace is monopolistic, with key players like Allergan, Bausch and Lomb, and Alcon dominating because of their strong product portfolio. Other corporations like Sun Pharmaceuticals and Alembic Pharmaceuticals are increasing their presence thru specializing in product approvals and preferred drug launches. Emerging players like Ocular Therapeutix and Eton Pharmaceutical are also aiming to advantage regulatory approvals.

Harrow has signed a address Santen Pharmaceutical Co., Ltd. To gather business rights for 6 branded ophthalmic merchandise, increasing its ophthalmic product portfolio.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2019-2032

Base Year 2023

Estimated Year 2024

Forecast Period 2024-2032

Historical Period 2019-2022

Growth Rate CAGR of 5.6% from 2024-2032

Unit Value (USD billion)

Segmentation By Drug Class

Antihistamines & Mast Cell Stabilizers
Corticosteroids
Others

By Disease Type

Mild Allergic Conjunctivitis
Severe Allergic Conjunctivitis

By Distribution Channel

Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Pharmacies

By Region

North America (By Drug Class, By Disease Type, By Distribution Channel, By Country)
U.S.
Canada
Europe (By Drug Class, By Disease Type, By Distribution Channel, By Country)
U.K.
Germany
France
Italy
Spain
Scandinavia
Rest of Europe
Asia Pacific (By Drug Class, By Disease Type, By Distribution Channel, By Country )
Japan
China
India
Australia
Southeast Asia
Rest of Asia Pacific
Latin America (By Drug Class, By Disease Type, By Distribution Channel, By Country)
Brazil
Mexico
Rest of Latin America
Middle East & Africa (By Drug Class, By Disease Type, By Distribution Channel, By Country)
GCC
South Africa
Rest of Middle East & Africa

Please Note: It will take 5-6 business days to complete the report upon order confirmation.

1. Introduction: 1.1. Research Scope; 1.2. Market Segmentation; 1.3. Research Methodology; 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics: 3.1. Market Drivers; 3.2. Market Restraints; 3.3. Market Opportunities; 3.4. Market Trends
4. Key Insights: 4.1. Prevalence of Allergic Conjunctivitis - By Key Countries, 2022/ 2023; 4.2. Pipeline Analysis, By Key Players; 4.3. Key Industry Developments, Mergers, Acquisitions, Etc.; 4.4. New Product Launches, By Key Players; 4.5. Impact of COVID-19 on the Market
5. Global Allergic Conjunctivitis Market Analysis, Insights and Forecast, 2019-2032: 5.1. Market Analysis, Insights and Forecast – By Drug Class; 5.1.1. Antihistamines & Mast Cell Stabilizers; 5.1.2. Corticosteroids; 5.1.3. Others; 5.2. Market Analysis, Insights and Forecast – By Disease Type; 5.2.1. Mild Allergic Conjunctivitis; 5.2.2. Severe Allergic Conjunctivitis; 5.3. Market Analysis, Insights and Forecast – By Distribution Channel; 5.3.1. Hospital Pharmacies; 5.3.2. Drug Stores & Retail Pharmacies; 5.3.3. Online Pharmacies; 5.4. Market Analysis, Insights and Forecast – By Region; 5.4.1. North America; 5.4.2. Europe; 5.4.3. Asia Pacific; 5.4.4. Latin America; 5.4.5. Middle East & Africa
6. North America Allergic Conjunctivitis Market Analysis, Insights and Forecast, 2019-2032: 6.1. Market Analysis, Insights and Forecast – By Drug Class; 6.1.1. Antihistamines & Mast Cell Stabilizers; 6.1.2. Corticosteroids; 6.1.3. Others; 6.2. Market Analysis, Insights and Forecast – By Disease Type; 6.2.1. Mild Allergic Conjunctivitis; 6.2.2. Severe Allergic Conjunctivitis; 6.3. Market Analysis, Insights and Forecast – By Distribution Channel; 6.3.1. Hospital Pharmacies; 6.3.2. Drug Stores & Retail Pharmacies; 6.3.3. Online Pharmacies; 6.4. Market Analysis, Insights and Forecast – By Country; 6.4.1. U.S.; 6.4.2. Canada
7. Europe Allergic Conjunctivitis Market Analysis, Insights and Forecast, 2019-2032: 7.1. Market Analysis, Insights and Forecast – By Drug Class; 7.1.1. Antihistamines & Mast Cell Stabilizers; 7.1.2. Corticosteroids; 7.1.3. Others; 7.2. Market Analysis, Insights and Forecast – By Disease Type; 7.2.1. Mild Allergic Conjunctivitis; 7.2.2. Severe Allergic Conjunctivitis; 7.3. Market Analysis, Insights and Forecast – By Distribution Channel; 7.3.1. Hospital Pharmacies; 7.3.2. Drug Stores & Retail Pharmacies; 7.3.3. Online Pharmacies; 7.4. Market Analysis, Insights and Forecast – By Country/ Sub-Region; 7.4.1. U.K.; 7.4.2. Germany; 7.4.3. France; 7.4.4. Spain; 7.4.5. Italy; 7.4.6. Scandinavia; 7.4.7. Rest of Europe
8. Asia Pacific Allergic Conjunctivitis Market Analysis, Insights and Forecast, 2019-2032: 8.1. Market Analysis, Insights and Forecast – By Drug Class; 8.1.1. Antihistamines & Mast Cell Stabilizers; 8.1.2. Corticosteroids; 8.1.3. Others; 8.2. Market Analysis, Insights and Forecast – By Disease Type; 8.2.1. Mild Allergic Conjunctivitis; 8.2.2. Severe Allergic Conjunctivitis; 8.3. Market Analysis, Insights and Forecast – By Distribution Channel; 8.3.1. Hospital Pharmacies; 8.3.2. Drug Stores & Retail Pharmacies; 8.3.3. Online Pharmacies; 8.4. Market Analysis, Insights and Forecast – By Country/ Sub-Region; 8.4.1. Japan; 8.4.2. China; 8.4.3. India; 8.4.4. Australia; 8.4.5. Southeast Asia; 8.4.6. Rest of Asia Pacific
9. Latin America Allergic Conjunctivitis Market Analysis, Insights and Forecast, 2019-2032: 9.1. Market Analysis, Insights and Forecast – By Drug Class; 9.1.1. Antihistamines & Mast Cell Stabilizers; 9.1.2. Corticosteroids; 9.1.3. Others; 9.2. Market Analysis, Insights and Forecast – By Disease Type; 9.2.1. Mild Allergic Conjunctivitis; 9.2.2. Severe Allergic Conjunctivitis; 9.3. Market Analysis, Insights and Forecast – By Distribution Channel; 9.3.1. Hospital Pharmacies; 9.3.2. Drug Stores & Retail Pharmacies; 9.3.3. Online Pharmacies; 9.4. Market Analysis, Insights and Forecast – By Country/ Sub-Region; 9.4.1. Brazil; 9.4.2. Mexico; 9.4.3. Rest of Latin America
10. Middle East & Africa Allergic Conjunctivitis Market Analysis, Insights and Forecast, 2019-2032: 10.1. Market Analysis, Insights and Forecast – By Drug Class; 10.1.1. Antihistamines & Mast Cell Stabilizers; 10.1.2. Corticosteroids; 10.1.3. Others; 10.2. Market Analysis, Insights and Forecast – By Disease Type; 10.2.1. Mild Allergic Conjunctivitis; 10.2.2. Severe Allergic Conjunctivitis; 10.3. Market Analysis, Insights and Forecast – By Distribution Channel; 10.3.1. Hospital Pharmacies; 10.3.2. Drug Stores & Retail Pharmacies; 10.3.3. Online Pharmacies; 10.4. Market Analysis, Insights and Forecast – By Country/ Sub-Region; 10.4.1. GCC Countries; 10.4.2. South Africa; 10.4.3. Rest of Middle East & Africa
11. Competitive Analysis: 11.1. Global Market Share Analysis (2023); 11.2. Company Profiles; 11.2.1. Allergan (AbbVie Inc.); 11.2.1.1. Overview; 11.2.1.2. Products; 11.2.1.3. SWOT Analysis; 11.2.1.4. Recent Developments; 11.2.1.5. Strategies; 11.2.1.6. Financials (Based On Availability); 11.2.2. Santen Pharmaceutical Co., Ltd.; 11.2.2.1. Overview; 11.2.2.2. Products; 11.2.2.3. SWOT Analysis; 11.2.2.4. Recent Developments; 11.2.2.5. Strategies; 11.2.2.6. Financials (Based On Availability); 11.2.3. Bausch & Lomb; 11.2.3.1. Overview; 11.2.3.2. Products; 11.2.3.3. SWOT Analysis; 11.2.3.4. Recent Developments; 11.2.3.5. Strategies; 11.2.3.6. Financials (Based On Availability); 11.2.4. Alcon; 11.2.4.1. Overview; 11.2.4.2. Products; 11.2.4.3. SWOT Analysis; 11.2.4.4. Recent Developments; 11.2.4.5. Strategies; 11.2.4.6. Financials (Based On Availability); 11.2.5. Novartis AG; 11.2.5.1. Overview; 11.2.5.2. Products; 11.2.5.3. SWOT Analysis; 11.2.5.4. Recent Developments; 11.2.5.5. Strategies; 11.2.5.6. Financials (Based On Availability); 11.2.6. Eyevance Pharmaceuticals LLC; 11.2.6.1. Overview; 11.2.6.2. Products; 11.2.6.3. SWOT Analysis; 11.2.6.4. Recent Developments; 11.2.6.5. Strategies; 11.2.6.6. Financials (Based On Availability); 11.2.7. Sun Pharmaceutical Industries Ltd.; 11.2.7.1. Overview; 11.2.7.2. Products; 11.2.7.3. SWOT Analysis; 11.2.7.4. Recent Developments; 11.2.7.5. Strategies; 11.2.7.6. Financials (Based On Availability); 11.2.8. Ocular Therapeutix, Inc.; 11.2.8.1. Overview; 11.2.8.2. Products; 11.2.8.3. SWOT Analysis; 11.2.8.4. Recent Developments; 11.2.8.5. Strategies; 11.2.8.6. Financials (Based On Availability); 11.2.9. Eton Pharmaceutical; 11.2.9.1. Overview; 11.2.9.2. Products; 11.2.9.3. SWOT Analysis; 11.2.9.4. Recent Developments; 11.2.9.5. Strategies; 11.2.9.6. Financials (Based On Availability)